research use only

Pilocarpine HCl AChR agonist

Cat.No.S4231

Pilocarpine HCl (NSC 5746) is a selective muscarinic acetylcholine receptor agonist used to produce an experimental model of epilepsy.
Jump to

Quality Control

Batch: Purity: 99.6621%
99.6621

Solubility

In vitro
Batch:

DMSO : 49 mg/mL (200.22 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 49 mg/mL

Ethanol : 49 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 244.72 Formula

C11H16N2O2.HCl

Storage (From the date of receipt)
CAS No. 54-71-7 Download SDF Storage of Stock Solutions

Synonyms NSC 5746 HCl SMILES CCC1C(COC1=O)CC2=CN=CN2C.Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
mAChR
In vitro
Pilocarpine is a parasympathomimetic alkaloid obtained from the leaves of tropical American shrubs from the genus Pilocarpus. It is a non-selective muscarinic receptor agonist in the parasympathetic nervous system, which acts therapeutically at themuscarinic acetylcholine receptor M3 due to its topical application, e.g., in glaucoma and xerostomia. Pilocarpine acts on a subtype of muscarinic receptor (M3) found on the iris sphincter muscle, causing the muscle to contract and engage in miosis. Pilocarpine also acts on the ciliary muscle and causes it to contract. When the ciliary muscle contracts, it opens the trabecular meshwork through increased tension on the scleral spur. This action facilitates the rate that aqueous humorleaves the eye to decrease intraocular pressure. In ophthalmology, pilocarpine is also used to reduce the possibility of glare at night from lights when the patient has undergone implantation of phakic intraocular lenses; the use of pilocarpine would reduce the size of the pupils, relieving these symptoms. The most common concentration for this use is pilocarpine 1%, the weakest concentration. Pilocarpine is also used to treat dry mouth (xerostomia) which can occur, for example, as a side effect of radiation therapy for head and neck cancers. Pilocarpine stimulates the secretion of large amounts of saliva and sweat.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-11-10)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03933631 RECRUITING
Glaucoma
Montefiore Medical Center
2019-05-01 PHASE3
NCT07012512 NOT_YET_RECRUITING
Pupillary Constriction; Accomodation
Mansoura University
2025-06-01
NCT06451666 UNKNOWN
Presbyopia
CSPC Ouyi Pharmaceutical Co., Ltd.
2024-06-30 PHASE3
NCT07113210 RECRUITING
Presbyopia; Glasses; Dry Eye
Southern College of Optometry
2025-07-18 PHASE4
NCT06783686 COMPLETED
Pupil Constriction
Novus Vision LLC
2025-01-30 EARLY_PHASE1
NCT05506137 UNKNOWN
Xerostomia; Dry Mouth
Maastricht University Medical Center
2023-01 PHASE3

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map